

Synaffix enables ADCs that are more effective, better tolerated, and easier to manufacture



About Synaffix


Synaffix BV is a Netherlands-based biotechnology company that has developed a best-in-class antibody-drug conjugate (ADC) technology platform that consistently delivers highly competitive targeted cancer therapeutics. The value proposition of the Synaffix platform is to deliver more effective and better tolerated ADCs. This has been consistently validated across numerous preclinical benchmarking studies versus all 3 major clinical-stage ADC technologies (see chart below). Our business model comprises technology out-licensing of our intellectual property portfolio, with granted claims that provide end-to-end patent protection on the entire platform thru at least 2035.

We anticipate first GMP batches of ADCs containing Synaffix technology to be manufactured by the end of 2017 and first-in-human studies to be initiated by our partners in 2018.

Key Features of Our ADC Technology Platform

- Highly stable ADC products (reduced aggregation and stable payload attachment)
- Cost of Goods competitive with marketed and clinical-stage ADCs
- Homogenous DAR2, DAR4 and Dual-Warhead DAR[2+2] ADC formats
- Demonstrated linear scalability to 15-gram scale
- Proven compatibility with all IgG isotypes and all key payload classes
- High-yield conversion of an antibody to a site-specific ADC without antibody engineering
- Efficient conjugation of highly hydrophobic payloads

Consistently Superior Efficacy in Multiple Cancers




Across numerous preclinical benchmarking studies that evaluate competing approaches, Synaffix technology consistently delivers ADCs with increased therapeutic index. The Synaffix ADC was prepared from the same antibody and payload as the benchmark ADC. MTD = Maximum Tolerated Dose in rats.

Differentiated vs. 3 Major Clinical-Stage Technologies

Approx. 60 active clinical-stage ADC programs currently

ADC Technology Generation	Antibody Conjugation Approach	# of Clinical Programs
1 st Gen	Random conjugation to naturally-occurring cysteines	36
1 st Gen	Random conjugation to naturally-occurring lysines	15
2 nd Gen	Site-specific conjugation to engineered cysteines (like Thiomab)	7
2 nd Gen	Site-specific conjugation to non-natural amino acids	2



SOURCE: Synaffix internal clinical ADC pipeline database

Management Team

Peter van de Sande, MSc, MBA, MBL
Chief Executive Officer

Floris van Delft, PhD
Founder & Chief Scientific Officer

Sander van Berkel, PhD
Founder & Director, R&D Operations

Anthony DeBoer
Director, Business Development

Board of Directors

Konstantinos Efthymiopoulos, PhD, MBA
Independent Chairman

Simon Nebel, PhD, MBA
Managing Partner
Aravis

Edward van Wezel, MSc
Managing Partner
BioGeneration Ventures

Hakan Goker, PhD
Senior Investment Director
Merck Ventures

Peter van de Sande, MSc, MBA, MBL
Chief Executive Officer

Scientific Advisory Board

Hans-Joachim Boehm, PhD
Former Global Head of
Small Molecule Research, Roche

Stan van Boeckel, PhD
Professor of Industrial Medicinal
Chemistry, Leiden Institute of Chemistry

Jason Chin, PhD
Professor of Chemistry & Chemical
Biology, University of Cambridge

Luca Gianni, MD
Director of Medical Oncology,
San Raffaele Hospital, Milan


George Sledge, MD
Professor and Chief of Medical Oncology,
Stanford University Medical Center

GlycoConnect™ Site-Specific Antibody Conjugation

GlycoConnect™ is a cutting-edge antibody-conjugation technology that represents the foundation of the Synaffix ADC technology platform. The value proposition of GlycoConnect™ is to enable ADCs that are both safer and more effective. This is achieved by securely attaching the payload site-specifically and securely to the naturally-occurring antibody glycan.

GlycoConnect™ is applied in 3 highly efficient steps, using our proprietary reagents:

1. **Trim** glycan is trimmed by endoglycosidase, creating a homogenous intermediate
2. **Tag** trimmed glycan is tagged with azidosugar by glycosyltransferase
3. **Connect** metal-free click chemistry securely attaches payload



GlycoConnect™ is highly efficient, going from antibody to purified ADC with > 75% overall yield.

HydraSpace™ ADC-Enhancing Spacer



HydraSpace™ is a highly polar, yet compact ADC-enhancing spacer technology that is complimentary to GlycoConnect™. It is incorporated into the linker-payload at one or multiple positions during synthesis and brings the following additional advantages:

- Further improves therapeutic index
- Improves PK and stability (reduced aggregation)
- Improves conjugation efficiency and speed
- Enables branching for higher drug loading
- Enables Dual-Warhead ADC which enhances efficacy due to two mechanisms of action

Granted IP on Entire Platform thru at Least 2035

The Synaffix IP portfolio is comprised of 18 granted patents and applications. With IP protection thru at least 2035, granted claims provide end-to-end patent protection of the Synaffix ADC technology spanning:

- **GlycoConnect™** site-specific antibody conjugation technology
- **HydraSpace™** ADC-enhancing spacer technology
- **BCN** best-in-class metal-free click chemistry



Technology Partnering

The business model of Synaffix comprises out-licensing of our platform ADC technology.

In just a few weeks, Synaffix can apply its proprietary ADC technology to a collaborator's antibody (and payload, if provided) to supply a few hundred milligrams of material for non-clinical proof-of-concept studies. If desired, Synaffix can also advise on the selection of payloads that benefit from freedom to operate.

With an established supply chain of proprietary components for GMP manufacturing and proven process scalability, we facilitate a rapid path to the clinic for new product candidates.

In October 2016, Synaffix entered into a commercial license agreement with Swiss-based ADC Therapeutics, the first announced of several undisclosed collaborations.



Contact

Pivot Park, RE Building
Industrielaan 63
5349 AE Oss, The Netherlands

(tel) +31 88 022 4505
(fax) +31 88 022 4555
bd@synaffix.com